TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.
The grant is founded by the Scientific and Technologic Development Program of Hailing District and supported by the Hailing District government. Our project is about the development of the key technologies used in medical herb planting pre-processing of raw materials for Directly-Oral TCMP products. The Company will develop a one-stop system from medical herb planting to the finished products of TCMPs, which enables the Company to track and ensure products' qualities. The Company is expected to further its lead on research and development of specialized Advanced TCMPs and receive additional benefits when marketing its new Advanced TCMP products in the future.
Dr. Jing-Zhen Deng, Chief Scientific Officer and Chief Operating Officer of China SXT, commented, "This grant supported by the local government can contribute to our continuous effort in leading research and development of new advanced TCMPs and chase of higher quality of the products. We believe it will further strengthen our R&D capabilities in our new Advanced TCMPs, which is expected to eventually help expanding our market share in our advanced Directly-Oral TCMP products."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding the closing of the proposed private placement are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; the growth of the pharmaceutical market, particularly the Traditional Chinese Medicine Pieces ("TCMPs") market, in China; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company serves and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward - looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Dr. Jing-Zhen Deng, COO & CSO
Email: jdeng@sxtchina.com or ir@sxtchina.com
Phone: 86-523-8629-9028
View original content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-that-it-received-a-grant-supported-by-city-government-301024801.html